Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

Yazan Madanat, Mikkael A. Sekeres

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that have a substantial impact on patients’ quality of life, in addition to causing significant morbidity and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the treatment of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, though, and given the lack of clear treatment guidelines after HMA treatment failure, it is imperative to optimize patient selection and identify the right timing of HMA treatment initiation and response evaluation to maximize patient benefit. Initiatives to improve outcomes have focused on HMA-based drug combinations to enhance HMA activity or treat MDS using complementary drug mechanisms of action. In this review, we will summarize the available data to aid decision-making while treating MDS patients with HMAs.

Original languageEnglish (US)
Pages (from-to)147-153
Number of pages7
JournalSeminars in Hematology
Volume54
Issue number3
DOIs
StatePublished - Jul 2017
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Azacitidine
decitabine
Drug Combinations
Hematopoietic Stem Cells
Treatment Failure
Acute Myeloid Leukemia
Patient Selection
Decision Making
Therapeutics
Quality of Life
Guidelines
Morbidity
Survival
Mortality
Pharmaceutical Preparations

Keywords

  • Azacitidine
  • Combination therapy
  • Decitabine
  • Molecular
  • Myelodysplastic syndromes
  • Response prediction

ASJC Scopus subject areas

  • Hematology

Cite this

Optimizing the use of hypomethylating agents in myelodysplastic syndromes : Selecting the candidate, predicting the response, and enhancing the activity. / Madanat, Yazan; Sekeres, Mikkael A.

In: Seminars in Hematology, Vol. 54, No. 3, 07.2017, p. 147-153.

Research output: Contribution to journalReview article

@article{e5fcd7ddc74940639983eb625deb0495,
title = "Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity",
abstract = "Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that have a substantial impact on patients’ quality of life, in addition to causing significant morbidity and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the treatment of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, though, and given the lack of clear treatment guidelines after HMA treatment failure, it is imperative to optimize patient selection and identify the right timing of HMA treatment initiation and response evaluation to maximize patient benefit. Initiatives to improve outcomes have focused on HMA-based drug combinations to enhance HMA activity or treat MDS using complementary drug mechanisms of action. In this review, we will summarize the available data to aid decision-making while treating MDS patients with HMAs.",
keywords = "Azacitidine, Combination therapy, Decitabine, Molecular, Myelodysplastic syndromes, Response prediction",
author = "Yazan Madanat and Sekeres, {Mikkael A.}",
year = "2017",
month = "7",
doi = "10.1053/j.seminhematol.2017.06.001",
language = "English (US)",
volume = "54",
pages = "147--153",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Optimizing the use of hypomethylating agents in myelodysplastic syndromes

T2 - Selecting the candidate, predicting the response, and enhancing the activity

AU - Madanat, Yazan

AU - Sekeres, Mikkael A.

PY - 2017/7

Y1 - 2017/7

N2 - Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that have a substantial impact on patients’ quality of life, in addition to causing significant morbidity and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the treatment of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, though, and given the lack of clear treatment guidelines after HMA treatment failure, it is imperative to optimize patient selection and identify the right timing of HMA treatment initiation and response evaluation to maximize patient benefit. Initiatives to improve outcomes have focused on HMA-based drug combinations to enhance HMA activity or treat MDS using complementary drug mechanisms of action. In this review, we will summarize the available data to aid decision-making while treating MDS patients with HMAs.

AB - Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that have a substantial impact on patients’ quality of life, in addition to causing significant morbidity and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the treatment of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, though, and given the lack of clear treatment guidelines after HMA treatment failure, it is imperative to optimize patient selection and identify the right timing of HMA treatment initiation and response evaluation to maximize patient benefit. Initiatives to improve outcomes have focused on HMA-based drug combinations to enhance HMA activity or treat MDS using complementary drug mechanisms of action. In this review, we will summarize the available data to aid decision-making while treating MDS patients with HMAs.

KW - Azacitidine

KW - Combination therapy

KW - Decitabine

KW - Molecular

KW - Myelodysplastic syndromes

KW - Response prediction

UR - http://www.scopus.com/inward/record.url?scp=85026432714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026432714&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2017.06.001

DO - 10.1053/j.seminhematol.2017.06.001

M3 - Review article

C2 - 28958288

AN - SCOPUS:85026432714

VL - 54

SP - 147

EP - 153

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3

ER -